BPC-157 vs GHK-Cu: two biohacker favorites, very different evidence bases
Both are Category 2 research peptides. Their evidence profiles, use cases, and plausible mechanisms have essentially nothing in common. Here's the honest contrast.
BPC-157 and GHK-Cu sit near the top of biohacker peptide interest for 2026, and both are on the FDA's Category 2 list. That's about where the similarities end. BPC-157 is a gastric-juice-derived fragment studied primarily for tissue repair and GI protection — with most of the research animal-based. GHK-Cu is a copper-binding tripeptide with decades of dermatology research supporting topical cosmetic use, and a separate, much thinner evidence base for systemic/injectable applications.
| Field | BPC-157 | GHK-Cu |
|---|---|---|
| Brand names | Body Protection Compound | Copper peptide |
| Manufacturer | Synthetic (research vendors) | Various (topical cosmetic + research vendors) |
| FDA approved | Not FDA approved; Category 2 (Sep 2023) | Topical cosmetic permitted; injectable Category 2 (Sep 2023) |
| Indication | Research: tissue repair, GI protection | Cosmetic (topical); research (injectable) |
| Mechanism | Proposed: VEGF upregulation, nitric oxide modulation | Collagen synthesis, copper redox, gene-expression modulation |
| Delivery | Research-use injection or oral | Topical serum (cosmetic); injection (research) |
Primary sources
Frequently asked
Which has more human evidence?
GHK-Cu, but only for topical cosmetic use. Topical GHK-Cu has decades of dermatology research. For injectable/systemic use, both have thin human evidence. For BPC-157 specifically, a 2025 PMC narrative review catalogued ~350 animal studies and flagged the concentration in one Croatian research group as a methodological concern.
Are either legal in the US right now?
Topical GHK-Cu is sold broadly in cosmetic products under FDA cosmetic regulation (The Ordinary Copper Peptides, NIOD, others). Injectable GHK-Cu and all BPC-157 are FDA Category 2 — cannot be legally compounded. The February 2026 HHS proposal may remove both from Category 2 pending FDA review.
Can I use them together?
There's no clinical evidence supporting a BPC-157 + GHK-Cu combination for any indication in humans. Biohacker protocols often suggest stacking, but this isn't evidence-based.